Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

Market Cap	102.82B +42.8%
Revenue (ttm)	45.04B +9.2%
Net Income	2.92B -14.6%
EPS	19.05 -15.1%
Shares Out	153.10M
PE Ratio	35.26
Forward PE	23.49
Dividend	1.00 (0.15%)
Ex-Dividend Date	Jul 3, 2026

Volume	111,565
Open	676.00
Previous Close	680.20
Day's Range	663.00 - 679.45
52-Week Range	409.30 - 838.80
Beta	0.56
Analysts	Strong Buy
Price Target	863.33 (+28.56%)
Earnings Date	Nov 4, 2026

About NSE:AKUMS

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 7,337
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AKUMS

Financial Performance

In fiscal year 2026, NSE:AKUMS's revenue was 43.61 billion, an increase of 5.84% compared to the previous year's 41.21 billion. Earnings were 2.55 billion, a decrease of -24.54%.

Analyst Summary

According to 3 analysts, the average rating for AKUMS stock is "Strong Buy." The 12-month stock price target is ₹863.33, which is an increase of 28.56% from the latest price.

Price Target

₹863.33

(28.56% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error